Gut microbiome and immunotherapy response

Taxonomic profiling of available faecal microbiome samples (n=43) showed significant differences between patients who responded to therapy (n=30) and those who did not (n=13; p

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology 2017-12, Vol.18 (12), p.e717-e717
1. Verfasser: Burki, Talha Khan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e717
container_issue 12
container_start_page e717
container_title The lancet oncology
container_volume 18
creator Burki, Talha Khan
description Taxonomic profiling of available faecal microbiome samples (n=43) showed significant differences between patients who responded to therapy (n=30) and those who did not (n=13; p
doi_str_mv 10.1016/S1470-2045(17)30841-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1963479292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204517308410</els_id><sourcerecordid>1963479292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-9f65b59bbb869892947d2afbc31993a048eb82c627930cf2f1c8201a50b0765c3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlZ_glLw0h5WM0l2k5xEilah4EE9h002iyndD5Ndof_etFs9ePE0YXjmncmD0CXgG8CQ3b4C4zghmKUz4HOKBYMEH6FxbLMkZUIc798DMkJnIawxBg44PUUjIoFIxrIxmi_7blo54xvtmspO87qYuqrq66b7sD5vt1NvQ9vUwZ6jkzLfBHtxqBP0_vjwtnhKVi_L58X9KjFU0i6RZZbqVGqtRSaFjGt4QfJSGwpS0hwzYbUgJiNcUmxKUoIRBEOeYo15lho6QbMht_XNZ29DpyoXjN1s8to2fVAgM8p4DCYRvf6Drpve1_G6SHEKIDiBSKUDFT8Zgrelar2rcr9VgNXOpdq7VDtRCrjau1Q4zl0d0ntd2eJ36kdeBO4GwEYdX856FYyztbGF89Z0qmjcPyu-AUG7gM0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1973118721</pqid></control><display><type>article</type><title>Gut microbiome and immunotherapy response</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Burki, Talha Khan</creator><creatorcontrib>Burki, Talha Khan</creatorcontrib><description>Taxonomic profiling of available faecal microbiome samples (n=43) showed significant differences between patients who responded to therapy (n=30) and those who did not (n=13; p&lt;0·01), although the oral microbiome between these patient groups did not differ (p=0·11). Co-author Jennifer Wargo (MD Anderson Cancer Center) theorised that the gastrointestinal bacteria are interacting with the immune cells that line the gut and might influence immunity through metabolites.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(17)30841-0</identifier><identifier>PMID: 29129446</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Bacteria ; Disease-Free Survival ; Faecalibacterium ; Female ; Gastrointestinal Microbiome - drug effects ; Gastrointestinal Microbiome - immunology ; Humans ; Immunotherapy ; Immunotherapy - methods ; Intestinal microflora ; Male ; Melanoma ; Melanoma - immunology ; Melanoma - mortality ; Melanoma - pathology ; Melanoma - therapy ; Mouth Mucosa - drug effects ; Mouth Mucosa - immunology ; Neoplasm Invasiveness - pathology ; Neoplasm Staging ; Predictive Value of Tests ; Programmed Cell Death 1 Receptor - antagonists &amp; inhibitors ; Proportional Hazards Models ; Risk Assessment ; Skin Neoplasms - immunology ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; Survival Analysis ; Treatment Outcome ; United States</subject><ispartof>The lancet oncology, 2017-12, Vol.18 (12), p.e717-e717</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Dec 1, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-9f65b59bbb869892947d2afbc31993a048eb82c627930cf2f1c8201a50b0765c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1973118721?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997,64387,64389,64391,72471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29129446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burki, Talha Khan</creatorcontrib><title>Gut microbiome and immunotherapy response</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Taxonomic profiling of available faecal microbiome samples (n=43) showed significant differences between patients who responded to therapy (n=30) and those who did not (n=13; p&lt;0·01), although the oral microbiome between these patient groups did not differ (p=0·11). Co-author Jennifer Wargo (MD Anderson Cancer Center) theorised that the gastrointestinal bacteria are interacting with the immune cells that line the gut and might influence immunity through metabolites.</description><subject>Bacteria</subject><subject>Disease-Free Survival</subject><subject>Faecalibacterium</subject><subject>Female</subject><subject>Gastrointestinal Microbiome - drug effects</subject><subject>Gastrointestinal Microbiome - immunology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Intestinal microflora</subject><subject>Male</subject><subject>Melanoma</subject><subject>Melanoma - immunology</subject><subject>Melanoma - mortality</subject><subject>Melanoma - pathology</subject><subject>Melanoma - therapy</subject><subject>Mouth Mucosa - drug effects</subject><subject>Mouth Mucosa - immunology</subject><subject>Neoplasm Invasiveness - pathology</subject><subject>Neoplasm Staging</subject><subject>Predictive Value of Tests</subject><subject>Programmed Cell Death 1 Receptor - antagonists &amp; inhibitors</subject><subject>Proportional Hazards Models</subject><subject>Risk Assessment</subject><subject>Skin Neoplasms - immunology</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>United States</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkE1LAzEQhoMotlZ_glLw0h5WM0l2k5xEilah4EE9h002iyndD5Ndof_etFs9ePE0YXjmncmD0CXgG8CQ3b4C4zghmKUz4HOKBYMEH6FxbLMkZUIc798DMkJnIawxBg44PUUjIoFIxrIxmi_7blo54xvtmspO87qYuqrq66b7sD5vt1NvQ9vUwZ6jkzLfBHtxqBP0_vjwtnhKVi_L58X9KjFU0i6RZZbqVGqtRSaFjGt4QfJSGwpS0hwzYbUgJiNcUmxKUoIRBEOeYo15lho6QbMht_XNZ29DpyoXjN1s8to2fVAgM8p4DCYRvf6Drpve1_G6SHEKIDiBSKUDFT8Zgrelar2rcr9VgNXOpdq7VDtRCrjau1Q4zl0d0ntd2eJ36kdeBO4GwEYdX856FYyztbGF89Z0qmjcPyu-AUG7gM0</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Burki, Talha Khan</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201712</creationdate><title>Gut microbiome and immunotherapy response</title><author>Burki, Talha Khan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-9f65b59bbb869892947d2afbc31993a048eb82c627930cf2f1c8201a50b0765c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Bacteria</topic><topic>Disease-Free Survival</topic><topic>Faecalibacterium</topic><topic>Female</topic><topic>Gastrointestinal Microbiome - drug effects</topic><topic>Gastrointestinal Microbiome - immunology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Intestinal microflora</topic><topic>Male</topic><topic>Melanoma</topic><topic>Melanoma - immunology</topic><topic>Melanoma - mortality</topic><topic>Melanoma - pathology</topic><topic>Melanoma - therapy</topic><topic>Mouth Mucosa - drug effects</topic><topic>Mouth Mucosa - immunology</topic><topic>Neoplasm Invasiveness - pathology</topic><topic>Neoplasm Staging</topic><topic>Predictive Value of Tests</topic><topic>Programmed Cell Death 1 Receptor - antagonists &amp; inhibitors</topic><topic>Proportional Hazards Models</topic><topic>Risk Assessment</topic><topic>Skin Neoplasms - immunology</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burki, Talha Khan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burki, Talha Khan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gut microbiome and immunotherapy response</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2017-12</date><risdate>2017</risdate><volume>18</volume><issue>12</issue><spage>e717</spage><epage>e717</epage><pages>e717-e717</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><abstract>Taxonomic profiling of available faecal microbiome samples (n=43) showed significant differences between patients who responded to therapy (n=30) and those who did not (n=13; p&lt;0·01), although the oral microbiome between these patient groups did not differ (p=0·11). Co-author Jennifer Wargo (MD Anderson Cancer Center) theorised that the gastrointestinal bacteria are interacting with the immune cells that line the gut and might influence immunity through metabolites.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29129446</pmid><doi>10.1016/S1470-2045(17)30841-0</doi></addata></record>
fulltext fulltext
identifier ISSN: 1470-2045
ispartof The lancet oncology, 2017-12, Vol.18 (12), p.e717-e717
issn 1470-2045
1474-5488
language eng
recordid cdi_proquest_miscellaneous_1963479292
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Bacteria
Disease-Free Survival
Faecalibacterium
Female
Gastrointestinal Microbiome - drug effects
Gastrointestinal Microbiome - immunology
Humans
Immunotherapy
Immunotherapy - methods
Intestinal microflora
Male
Melanoma
Melanoma - immunology
Melanoma - mortality
Melanoma - pathology
Melanoma - therapy
Mouth Mucosa - drug effects
Mouth Mucosa - immunology
Neoplasm Invasiveness - pathology
Neoplasm Staging
Predictive Value of Tests
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Proportional Hazards Models
Risk Assessment
Skin Neoplasms - immunology
Skin Neoplasms - mortality
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Survival Analysis
Treatment Outcome
United States
title Gut microbiome and immunotherapy response
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T17%3A11%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gut%20microbiome%20and%20immunotherapy%20response&rft.jtitle=The%20lancet%20oncology&rft.au=Burki,%20Talha%20Khan&rft.date=2017-12&rft.volume=18&rft.issue=12&rft.spage=e717&rft.epage=e717&rft.pages=e717-e717&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(17)30841-0&rft_dat=%3Cproquest_cross%3E1963479292%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1973118721&rft_id=info:pmid/29129446&rft_els_id=S1470204517308410&rfr_iscdi=true